Filing Flows › Ginkgo Bioworks Holdings (DNA) › Q2 2026 › vs Q1 2026
Ginkgo Bioworks Holdings (DNA) Q2 2026 vs Q1 2026 (quarter over quarter)
Ginkgo Bioworks Holdings's revenue rose $682K (+4%) from $19.5M in Q1 2026 to $20.2M in Q2 2026.
Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%, net loss $46.7M, operating cash flow −$44.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $20.2M | $19.5M | $682K | +4% |
| Other income, net | $12.0M | −$11.3M | $23.3M | — |
| Net loss | $46.7M | $82.6M | −$35.9M | -43% |
| Costs & expenses | $78.8M | $102M | −$23.3M | -23% |
| Operating costs | $78.7M | $90.8M | −$12.1M | -13% |
| Income tax | $128K | −$80K | $208K | — |
| Cost of revenue | $1.7M | $3.1M | −$1.4M | -45% |
| Research & development | $46.2M | $49.9M | −$3.7M | -7% |
| General & admin | $30.8M | $37.8M | −$7.1M | -19% |
| Operating cash sources | $64.2M | $75.3M | −$11.2M | -15% |
| Depreciation & amortization | $12.3M | $12.8M | −$484K | -4% |
| Share-based compensation | $7.6M | $15.9M | −$8.3M | -52% |
| Cash used in operations | $44.3M | $46.7M | −$2.4M | -5% |
| Net loss absorbed | $46.7M | $82.6M | −$35.9M | -43% |
| Working capital & other | $17.5M | −$7.2M | $24.7M | — |
Questions
How much did Ginkgo Bioworks Holdings's revenue grow quarter over quarter in Q2 2026?
Ginkgo Bioworks Holdings's revenue rose $682K (+4%) from $19.5M in Q1 2026 to $20.2M in Q2 2026.